[go: up one dir, main page]

BRPI0416187A - método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i - Google Patents

método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i

Info

Publication number
BRPI0416187A
BRPI0416187A BRPI0416187-4A BRPI0416187A BRPI0416187A BR PI0416187 A BRPI0416187 A BR PI0416187A BR PI0416187 A BRPI0416187 A BR PI0416187A BR PI0416187 A BRPI0416187 A BR PI0416187A
Authority
BR
Brazil
Prior art keywords
fusion
present
class
viruses
initiation region
Prior art date
Application number
BRPI0416187-4A
Other languages
English (en)
Inventor
Robert F Garry
Russell B Wilson
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BRPI0416187A publication Critical patent/BRPI0416187A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

"MéTODO DE PREVENIR FUSãO DE VìRUS: CéLULA INIBINDO A FUNçãO DA REGIãO DE INICIAçãO DE FUSãO EM VìRUS DE RNA TENDO PROTEìNAS DE ENVELOPE FUSOGêNICO DE MEMBRANA DA CLASSE I". A presente invenção refere-se a um método de prevenir ou inibir infecção viral de uma célula e/ou fusão entre o envelope de um vírus e as membranas de uma célula alvejada pelo vírus (assim prevenindo liberação do genoma viral no citoplasma da célula, uma etapa requerida para infecção viral). A presente invenção particularmente refere-se às famílias de vírus de RNA, incluindo os arenavírus, coronavírus, filovírus, ortomixovírus, paramixovírus e retrovírus, tendo proteínas de fusão de membrana da classe I como as proteínas de fusão que medeiam este processo de fusão. A presente invenção fornece um método de identificar um motivo ou domínio conservado denominado a região de iniciação de fusão (FIR) nestes vírus. A presente invenção também fornece métodos de prevenir infecção por tais vírus, interferindo com sua FIR. A presente invenção também fornece métodos de tratamento e profilaxia de doenças induzidas por tais vírus.
BRPI0416187-4A 2003-11-04 2004-11-03 método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i BRPI0416187A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51718103P 2003-11-04 2003-11-04
PCT/US2004/036578 WO2005044992A2 (en) 2003-11-04 2004-11-03 Fusion initiation region in rna virus envelope proteins

Publications (1)

Publication Number Publication Date
BRPI0416187A true BRPI0416187A (pt) 2007-01-23

Family

ID=34572923

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416187-4A BRPI0416187A (pt) 2003-11-04 2004-11-03 método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i

Country Status (12)

Country Link
US (5) US7491793B2 (pt)
EP (7) EP2261374B1 (pt)
JP (1) JP5008398B2 (pt)
AT (1) ATE518967T1 (pt)
AU (2) AU2004288218B2 (pt)
BR (1) BRPI0416187A (pt)
CA (1) CA2544848C (pt)
DK (7) DK2261376T3 (pt)
ES (7) ES2437858T3 (pt)
PL (4) PL2261377T3 (pt)
PT (4) PT2261377E (pt)
WO (1) WO2005044992A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2261377T3 (pl) 2003-11-04 2014-03-31 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US8222204B2 (en) * 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
MX2009013635A (es) * 2007-06-25 2010-05-19 Univ Tulane Composiciones que inhiben la influenza y metodos.
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US10138276B2 (en) * 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
EP2528622A2 (en) 2010-01-26 2012-12-05 The Regents of the University of Colorado Influenza virus epitopes templated into double-stranded coiled coils and use thereof in immunization
JP2013520172A (ja) * 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US20130289246A1 (en) * 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US9060972B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
WO2016049380A1 (en) * 2014-09-24 2016-03-31 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2022521819A (ja) 2019-03-25 2022-04-12 ビステラ， インコーポレイテッド インフルエンザを処置および予防するための組成物および方法
US20230014151A1 (en) * 2019-09-04 2023-01-19 The Trustees Of Columbia University In The City Of New York Combination antiviral therapy for measles
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
JP7598538B2 (ja) * 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
CN117396492A (zh) * 2021-03-30 2024-01-12 贝勒医学院 用于基于多肽的高效蛋白抑制的方法和组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
JPH11209281A (ja) * 1998-01-21 1999-08-03 Daikin Ind Ltd ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2000059932A1 (fr) * 1999-03-31 2000-10-12 Otsuka Pharmaceutical Co., Ltd. Peptides se liant a l'hemagglutinine du virus de la grippe
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU7089600A (en) * 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6605427B2 (en) * 2000-02-10 2003-08-12 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
GB0022969D0 (en) 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
DE60143668D1 (de) * 2000-09-22 2011-01-27 Whitehead Biomedical Inst Peptidinhibitoren gegen den eintritt von hiv in zellen
US7731975B2 (en) * 2001-01-31 2010-06-08 The United States Of America As Represented By The Secretary Of The Army Chimeric filovirus glycoprotein
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
JP4651213B2 (ja) * 2001-03-27 2011-03-16 株式会社グライコメディクス インフルエンザウイルス・ヘマグルチニン結合性ペプチド
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
NZ592340A (en) * 2001-03-27 2012-12-21 Elenore S Bogoch A method for making a virus vaccine compising Replikin peptides
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
WO2005016238A2 (en) 2003-05-08 2005-02-24 Duke University Severe acute respiratory syndrome
WO2004111081A2 (en) * 2003-06-13 2004-12-23 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
AU2004259750A1 (en) * 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Soluble fragments of the SARS-CoV spike glycoprotein
PL2261377T3 (pl) 2003-11-04 2014-03-31 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus: komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I

Also Published As

Publication number Publication date
PT2261376E (pt) 2013-09-23
PT1692265E (pt) 2011-10-11
DK2261376T3 (da) 2013-10-07
US20060280754A1 (en) 2006-12-14
PT2261378E (pt) 2013-12-09
EP1692265A4 (en) 2007-08-29
DK2261375T3 (da) 2013-04-22
HK1152086A1 (en) 2012-02-17
EP2261380A2 (en) 2010-12-15
HK1152085A1 (en) 2012-02-17
JP5008398B2 (ja) 2012-08-22
PT2261377E (pt) 2013-11-29
EP2261377A3 (en) 2011-05-18
ES2427847T3 (es) 2013-11-04
EP2261374A2 (en) 2010-12-15
EP2261376A2 (en) 2010-12-15
EP2261378A2 (en) 2010-12-15
HK1152081A1 (en) 2012-02-17
EP2261375A2 (en) 2010-12-15
DK2261374T3 (da) 2012-09-10
US20150239940A1 (en) 2015-08-27
JP2007514408A (ja) 2007-06-07
US20090264362A1 (en) 2009-10-22
AU2010201046A1 (en) 2010-04-08
EP2261376B1 (en) 2013-07-10
US7491793B2 (en) 2009-02-17
US8598116B2 (en) 2013-12-03
US9725487B2 (en) 2017-08-08
EP2261377B1 (en) 2013-10-02
EP2261376A3 (en) 2011-02-23
ES2392891T3 (es) 2012-12-14
ATE518967T1 (de) 2011-08-15
PL2261377T3 (pl) 2014-03-31
ES2425600T3 (es) 2013-10-16
EP2261377A2 (en) 2010-12-15
DK2261377T3 (da) 2014-01-06
ES2372633T3 (es) 2012-01-25
EP2261374B1 (en) 2012-06-06
WO2005044992A2 (en) 2005-05-19
ES2400456T3 (es) 2013-04-10
AU2004288218A1 (en) 2005-05-19
WO2005044992A3 (en) 2006-12-07
EP2261378B1 (en) 2013-10-09
HK1152082A1 (en) 2012-02-17
ES2435941T3 (es) 2013-12-26
CA2544848C (en) 2015-12-29
US20120289458A1 (en) 2012-11-15
EP2261380A3 (en) 2011-02-23
EP2261378A3 (en) 2011-06-15
EP1692265B1 (en) 2011-08-03
US20140045743A1 (en) 2014-02-13
DK2261380T3 (da) 2013-10-07
EP2261380B1 (en) 2013-07-17
PL2261376T3 (pl) 2014-04-30
HK1152083A1 (en) 2012-02-17
EP2261375B1 (en) 2013-01-23
EP2261374A3 (en) 2011-03-02
EP2261375A3 (en) 2011-06-22
HK1152084A1 (en) 2012-02-17
US9056900B2 (en) 2015-06-16
PL2261378T3 (pl) 2014-03-31
EP1692265A2 (en) 2006-08-23
AU2004288218B2 (en) 2009-12-24
AU2010201046B2 (en) 2013-06-27
PL1692265T3 (pl) 2011-12-30
CA2544848A1 (en) 2005-05-19
ES2437858T3 (es) 2014-01-14
DK2261378T3 (da) 2014-01-20
DK1692265T3 (da) 2011-11-21

Similar Documents

Publication Publication Date Title
BRPI0416187A (pt) método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
Albarino et al. Efficient reverse genetics generation of infectious Junin viruses differing in glycoprotein processing
EP1507791A4 (en) ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION
NZ598000A (en) Composition for treating hbv infection
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EP1623012A4 (en) ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
NO20052058L (no) Behandling av influensa.
DE602005025751D1 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
Iwasaki et al. General molecular strategy for development of arenavirus live-attenuated vaccines
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
Scheidler et al. Inactivation of viruses by β-propiolactone in human cyro poor plasma and IgG concentrates
WO2010014248A3 (en) Antiviral activity of the protein scytovirin and methods of use
BRPI0418093A (pt) vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral
PH12022553394A1 (en) Conjugate of double-stranded sirna analogue
Ellenberg et al. Synthesis and expression of viral antigens in Vero cells persistently infected with Junin virus
Madsen Dependence of Two Arboviruses on the Host MicroRNA Pathway
MY146370A (en) Classical swine fever tissue culture live vaccine virus, the tissue culture method of the same and classical swine fever tissue culture live vaccine comprising the same
DE50309164D1 (de) Verwendung von amphiphilen nucleosid-phosphonoameisensäure-derivaten zur behandlung von viralen infektionskrankheiten
TW200738626A (en) Methods for treating hepatitis C

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 020120000076/RJ DE 02/01/2012, E NECESSARIO COMPLEMENTAR A GUIA RELATIVA A CESSAO, BEM COMO RECOLHER A GUIA REFERENTE A ESTA EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: AUTOIMMUNE TECHNOLOGIES, LLC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

B25G Requested change of headquarter approved

Owner name: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL